Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?

• Immune checkpoint inhibitors are approved for all mismatch repair deficient tumors. • Although rare, autoimmune myositis complicating pembrolizumab therapy may be fatal. • In this case, pembrolizumab caused rhabdomyolysis but also a durable response. • Severe autoimmune reaction may be associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Khetan, Varun, Blake, Erin A., Ciccone, Marcia A., Matsuo, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815810/
https://www.ncbi.nlm.nih.gov/pubmed/33511262
http://dx.doi.org/10.1016/j.gore.2021.100700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815810/
https://www.ncbi.nlm.nih.gov/pubmed/33511262
http://dx.doi.org/10.1016/j.gore.2021.100700

Ejemplares similares